NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
12.91
-0.13 (-1.00%)
At close: Mar 9, 2026, 4:00 PM EDT
12.91
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:02 PM EDT
Company Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NovoCure Limited
| Country | Switzerland |
| Founded | 2000 |
| IPO Date | Oct 2, 2015 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1,605 |
| CEO | Frank Leonard |
Contact Details
Address: Neuhofstrasse 21 Baar, 6340 Switzerland | |
| Website | novocure.com |
Stock Details
| Ticker Symbol | NVCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645113 |
| CUSIP Number | G6674U108 |
| ISIN Number | JE00BYSS4X48 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Frank Leonard | Chief Executive Officer |
| William F. Doyle | Executive Chairman |
| Barak Ben-Arye | General Counsel |
| Christoph Brackmann | Chief Financial Officer |
| Mukund Paravasthu | Chief Operating Officer |
| Michael Puri | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2026 | 144 | Filing |
| Mar 4, 2026 | 144 | Filing |
| Mar 4, 2026 | 144 | Filing |
| Mar 4, 2026 | 144 | Filing |
| Mar 4, 2026 | 144 | Filing |
| Mar 3, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Feb 27, 2026 | 144 | Filing |
| Feb 27, 2026 | 144 | Filing |